行情

RGNX

RGNX

Regenxbio
NASDAQ

实时行情|Nasdaq Last Sale

33.88
+1.34
+4.12%
盘后: 33.88 0 0.00% 16:56 03/27 EDT
开盘
30.97
昨收
32.54
最高
34.56
最低
30.23
成交量
56.79万
成交额
--
52周最高
59.98
52周最低
20.03
市值
12.58亿
市盈率(TTM)
-13.1191
分时
5日
1月
3月
1年
5年

分析师评级

6位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测RGNX价格均价为75.83,最高价位150.00,最低价为37.00。

EPS

RGNX 新闻

更多
  • 新加坡出台新规:公共场所不保持一米距离或将入狱
  • 澎湃新闻 · 3小时前
  • 安倍呼吁日本民众做好防疫持久战准备 暂不宣布进入紧急状态
  • 海外网 · 3小时前
  • 美股与美国经济,谁带崩了谁?
  • 证券市场红周刊 · 3小时前
  • 5G iPhone仍有望如期推出 供应商否认被告知延迟出货
  • TechWeb · 3小时前

所属板块

生物技术和医学研究
-2.43%
制药与医学研究
-0.87%

热门股票

代码
价格
涨跌幅

RGNX 简况

REGENXBIO Inc. is a clinical-stage biotechnology company. The Company's gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases. Its product candidate, RGX-314, is meant for the treatment of wet age-related macular degeneration (wet AMD). Its product candidate, RGX-501, is meant for the treatment of homozygous familial hypercholesterolemia (HoFH). It is also developing product candidates, such as RGX-111 and RGX-121, to address the neurological symptoms of two severe genetic lysosomal storage diseases, Mucopolysaccharidosis Type I (MPS I) and Mucopolysaccharidosis Type II (MPS II), respectively. Its product candidates utilize viral vectors from its gene delivery platform, NAV Technology Platform.
展开

微牛提供Regenxbio Inc(NASDAQ-RGNX)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的RGNX股票新闻,以帮助您做出投资决策。